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Abstract
Background: Bipolar disorder (BD) and borderline personality disorder (BPD) both are severe and chronic
psychiatric disorders. Both disorders have overlapping symptoms, and current research shows that the presence of
a BPD has an adverse effect on the course of BD. The limited research available shows an unfavorable illness course,
a worse prognosis and response to medication, longer treatment duration, more frequent psychiatric admissions,
higher drop-out, increased risk of substance abuse, increased risk of suicide, and more impairment of social and
occupational functioning. However, there is no research available on the effect of specific psychotherapeutic
treatment for this patients.
Methods/Design: This paper presents the protocol of a RCT to investigate the presence of borderline personality
features in patients treated for BD (study part 1) and the effectiveness of STEPPS (Systems Training for Emotional
Predictability and Problem Solving) added to treatment as usual (TAU) for BD compared to TAU in patients with BD
and comorbid borderline personality features (study part 2). STEPPS is a validated and effective intervention for BPD.
The study population consists of patients treated for BD at specialized outpatient clinics for BD in the Netherlands.
At first the prevalence of comorbid borderline personality features in outpatients with BD is investigated. Inclusion
criteria for study part 2 is defined as having three or more of the DSM-IV-TR diagnostic criteria of BPD, including
impulsivity and anger bursts. Primary outcomes will be the frequency and severity of manic and depressive
recurrences as well as severity, course and burden of borderline personality features. Secondary outcomes will
be quality of life, utilizing mental healthcare and psychopathologic symptoms not primarily related to BD or BPD.
Assessment will be at baseline, at the end of the intervention, and at 12 and 18 months follow-up.
Discussion: This will be the first randomized controlled trial of a specific intervention in patients with BD and
comorbid BPD or borderline personality features. There are no recommendations in the guideline of treatment of
bipolar disorders for patients with this complex comorbidity. We expect that a combined treatment aimed at mood
disorder and emotion regulation will improve treatment outcomes for these patients.
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Background
Bipolar disorder (BD) is a complex and heterogeneous
mood disorder defined by the occurrence of depressive,
manic, hypomanic, and mixed episodes, divided by inter-
vals of longer or shorter duration. DSM-IV-TR [1] classi-
fication distinguishes bipolar I disorder (BD-I), bipolar II
disorder (BD-II), bipolar disorder Not Otherwise Specified
(BD-NOS), and cyclothymia. A study of the World
Health Organization [2] reported that BD is associated
with significant functional impairment. There are con-
siderable differences in the acute and prophylactic
treatment response among patients with BD. Longitudinal
studies show that despite treatment there are often recur-
rent episodes, residual symptoms, cognitive and psycho-
social impairments and functional limitations [3]. Many
questions regarding the course and outcome of BD and
factors that lead to an unfavorable outcome are still open
to research. There is evidence that the presence of comor-
bid personality disorder (PD) has an unfavorable impact
on the course of BD [4]. Patients with BD and comorbid
PD are more likely to be hospitalized, need more time to
achieve symptomatic remission, have more chronic im-
pairments in occupational and social functioning, are less
compliant to medication, have greater levels of suicidality,
and utilize more psychiatric services than patients with
BD without PD [5]. A review reported that BD patients
have a significantly higher prevalence of PD than the gen-
eral population [6]. The prevalence of PD in patients with
bipolar disorder is estimated between 30% and 40% [7-10].
This concerns particularly personality disorders from the
B and C clusters and in particular borderline personality
disorder (BPD). There are considerable areas of clinical
overlap between BD and BPD, especially mood instability
[11]. In a sample of 375 patients with a bipolar I or II dis-
order prevalence of BPD was estimated at 37.3% as
screened by PDQ-4+, specified as 34,3% in 169 patients
who were euthymic at the time of completing the PDQ-
4+, 36,8% in 163 depressed patients, and 51.2% in 43
patients with current (hypo-) mania (personal communi-
cation R. Kupka: unpublished data from the Stanley Foun-
dation Bipolar Network). Patients who meet diagnostic
criteria for both disorders (BD and BPD) have more fre-
quently a history of substance abuse [12]. Furthermore
there is evidence that the presence of comorbid PD has a
negative impact on the course of BD, leading to more
mixed episodes and depressive symptoms, a higher suicide
risk, a worse therapeutic response, and less treatment ad-
herence [13]. Given the overlap in clinical presentation of
BD and BPD, it has been suggested that there are shared
underlying pathophysiological mechanisms [14], [15].
Only three publications report the effectiveness of treat-
ment of BD with comorbid BPD. In a matched case–con-
trol study Swartz et al. [16] compared patients who met
diagnostic criteria for both BD and BPD with patients with
BD without BPD. Both groups received pharmacotherapy
and psychotherapy. The results suggest that treatment
course may be longer in patients suffering from both BD
and BPD. Preston et al. [12] observed that dimensions of
BPD improved significantly with lamotrigine treatment.
There was a trend for comorbid bipolar patients to require
a second psychoactive medication in addition to lamotri-
gine during extended treatment. Frankenburg and Zanarini
[17] compared in a placebo-controlled double-blind study
the efficacy of divalproex sodium in the treatment of
women with BPD and comorbid BD-II. They found that
treatment with divalproex sodium significantly decreased
irritability and anger, tempestuousness in relationships, and
impulsive aggressiveness.
Currently little research exists on the effects of psy-
chological treatments in patients with BD and comorbid
borderline personality features or BPD. There are no
specific recommendations included in the guidelines for
the treatment of BD in this population (e.g., the Dutch
guideline [18]). There clearly is a need to develop new
psychotherapies or evaluate existing psychological inter-
ventions to improve the course of BD and quality of life
as well as reducing mental health care utilization in these
patients. This study evaluates the addition of STEPPS
(Systems Training for Emotional Predictability and Problem
Solving) to treatment as usual (TAU) in patients with
BD and comorbid BPD or borderline personality features
as described in the inclusion criteria. STEPPS is a cogni-
tive behavioral skills group treatment for BPD developed
to improve their emotion regulation. The training consists
of 20 weekly sessions of approximately 2,5 hours and has
4 parts: psycho-education, emotion regulation skills, be-
havioral skills, and emotion handling plan. Two trainers
deliver the training. The group size is 8–12 patients. An
uncontrolled pilot study presented an indication of the ef-
fectiveness of the STEPPS in BPD [19]. A randomized trial
[20] showed that BPD patients treated with STEPPS com-
pared with TAU showed larger reduction of BPD symp-
toms, more quality of life and less general psychological
symptoms. All improvements were still significant after
6 months. In another randomized trial [21] STEPPS plus
TAU also led to greater improvements in impulsivity,
negative affectivity, mood, and global functioning. STEPPS
is included in the Dutch guidelines for treatment in BPD
[22]. The underlying assumption is that BPD is character-
ized by a defect in the individual’s internal ability to regu-
late emotional intensity. The aim of the training is to gain
skills to manage emotions and behavior related problems.
Friends and family members provide the “reinforcement
team” and learn to reinforce and support newly learned
skills of the patients (www.steppsforbpd.com).
BPD can be conceptualized as a dimensional or
spectrum disorder. Patients may suffer from significant
symptoms of BPD without meeting the full diagnostic
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criteria defined by DSM-IV-TR. To increase the clinical
relevance of the present study, both patients with BPD
as well as those with borderline personality features are
included. For this study patients with borderline person-
ality features are included if they have three or more of
the DSM-IV-TR diagnostic criteria, with the additional
requirement that these include both impulsivity and
anger bursts, since STEPPS training is specifically aimed
at improving skills to regulate these symptoms.
The study described in this article will investigate the
presence of borderline personality features in patients
treated for BD (study part 1). Furthermore it will be investi-
gated in a randomised controlled trial if a specific treatment
(STEPPS combined with TAU) compared to TAU only will
lead to better clinical outcomes as well as an increased
quality of life and less care consumptions (study part 2).
Methods
Design
Study part 1
Screening for personality disorder with a questionnaire
(PDQ4+) in patients with BD treated in a specialized out-
patient facility, followed by a semi-structured diagnostic
interview (SCID-II) in those patients who screened posi-
tive on BPD or borderline personality features relevant for
this study. Figure 1 shows the flow chart of study 1.
Study part 2
A multicenter randomized controlled trial in outpatients
with BD and comorbid BPD or borderline personality fea-
tures. The trial will be carried out in specialized outpatient
clinics for BD of large mental health institution in the
Netherlands. The inclusion period including all follow-up
measurements will be one and a half year. The duration of
the intervention phase is 20 weeks. Patients will be re-
cruited through treating psychologist, nurses and psych-
iatrist. Figure 2 shows the participant flow of the RCT.
Participants
Participants of study part 1 are BD patients aged 18–
65 years who are currently receiving treatment in special-
ized outpatient clinics for BD of large mental health
institution in the Netherlands. All participants from study
part 1 meet the DSM-IV-TR diagnosis criteria of BD-I, BD-II
or BD-NOS, verified by Mini-International Neuropsychiatric
Interview – Plus [23]. Respondents who fulfill the criteria
for BPD or borderline personality features according to
the definition of this study are invited to participate in
study part 2. They are approached by letter or are referred
by their treating clinicians. Patients receive both written
and oral information and signed informed consent, in and
exclusion criteria are checked.
Inclusion criteria
Patients age 18 – 65, diagnosed with BD (BD-I, BD-II
and BD-NOS) and comorbid BPD or borderline person-
ality features (at least 3 of 9 DSM-IV-TR criteria for
BPD, including both impulsivity and anger bursts).
Exclusion criteria
Patients with currently severe depressive (score on the
Invertory of depressive Symptoms, self-rated version IDS-
SR [24] > 38) or manic symptoms (score on the Young
Mania Rating Scale YMRS [25] > 20) are excluded from
the study. Other exclusion criteria are: currently having a
separate treatment for substance abuse; currently receiv-
ing a separate psychotherapy; having received STEPPS
within the last two years or receiving STEPPS currently;
being unable to comply with the STEPPS protocol; and
being unable to understand the Dutch language.
Objectives
Study part 1
Primary objective:
 To investigate the prevalence of borderline
personality features in outpatients with BD.
PDQ-4+ SCID-II MINI-PLUS Prevalence BD
(screening DSM-IV (classiﬁcaon (classiﬁcaon with BPF & BPD
Axis-II) DSM-IV Axis-II) DSM-IV Axis-I)
Paents BPD posive BPF posive BD posive BPF & BPD posive
with the
diagnosis
BD (incl.
Subtype I,
II & NOS) BPD negave BPF negave BD negave
Figure 1 Flow chart study 1. BD = bipolar disorder, BPD = borderline personality disorder, BPF = borderline personality features, NOS = not
otherwise specified.
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Study part 2
Primary objectives:
 To investigate the effectiveness of STEPPS added to
TAU on the symptoms and course of BD in patients
with BD and comorbid borderline personality
features.
 To investigate whether addition of STEPPS to TAU
is differently associated with a decrease of frequency
and severity of manic, hypomanic or depressive
episodes.
 To investigate the effectiveness of STEPPS added to
TAU on the symptoms, course and burden of
borderline personality features.
Secondary objectives:
 To investigate whether addition of STEPPS to TAU
is associated with an increase of quality of life.
 To investigate whether addition of STEPPS to TAU
is associated with a decrease of utilizing mental
healthcare.
 To investigate whether addition of STEPPS to TAU
is associated with a decrease of psychiatric
symptoms not primarily related to BD or borderline
personality features.
Procedure and outcome measures
Study part 1: The aim of study part 1 is to investigate
the prevalence of borderline personality features in pa-
tients with a diagnosis of BD. After informed consent all
patients with the diagnosis of BD are asked to complete
the Personality Disorder Questionnaire-4+ (PDQ-4+ [26],
Dutch translation [27]) to screen for the prevalence of
BPD. After screening all patients who score positively
on the presence of BPD will be asked to participate in
a Structured Clinical Interview for DSM-IV Personality
Disorders (SCID-II) [28]; Dutch translation [29]. The
SCID-II will start with modules concerning BPD. In case
of the presence of three BPD symptoms, including both
impulsivity and anger bursts, the interview will be contin-
ued with modules of other personality disorders to explore
further axis-II comorbidity. In case of presence of less
than three BPD symptoms (including both impulsivity and
anger burst) the interview will be terminated. The diagnosis
of BD (inclusive subtype I, II & NOS) will be verified with
modules A (depression), C (suicidality) and D (mania) of
the MINI-Plus [23]. Modules K & L will be completed to
determine substance abuse, and module M part I & II will
be completed to exclude schizoaffective disorder. In pa-
tients who were previously assessed with the MINI-Plus, a
re-test will be completed only if the information is older
than 2 years.
Study part 2: After inclusion into the trial patients are
randomly assigned either to the STEPPS added to treat-
ment as usual (TAU) for bipolar disorder or the control
group receiving TAU for BD only. Patients in the inter-
vention group will be assessed on all outcome measures
at baseline (T0), at the end of the intervention (T1) and
12 (T2) and 18 (T3) months after start of treatment.
Patients in the TAU control group will be assessed at base-
line and at corresponding intervals. The course of BD and
utilization of mental healthcare (number of consultations)
is measured with the prospective version of the Life Chart
Methodology (LCM) [30]. At baseline all patients will
be assessed with the Borderline Personality Severity Index
(BPDSI) for severity of borderline symptoms [31], the
Brief Symptom Inventory (BSI) [32] for severity of general
psychological symptoms, the Inventory of Depressive
Symptomatology (IDS-SR) [24] for severity of depressive
symptoms, and the Young Mania Rating Scale (YMRS)
[25] for severity of manic symptoms. The burden of
borderline symptoms will be assessed with the Borderline
Personality Disorder Checklist (BPDC-47) [33] and
Personality Assessment Inventory – Borderline Features
(PAI-BOR) [34]. Quality of life will be measured with the
Outcome Questionnaire (OQ-45) [35] and World Health
Organization Quality of Life short version (WHOQol Bref)
Figure 2 Flow chart study 2. BD = bipolar disorder, BPF = borderline personality features, TAU = treatment as usual, STEPPS = Systems Training
for Emotional Predictability and Problem Solving.
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[36]. Patient empowerment will be assessed with the
Patient Activation Measure (PAM) [37]. To assess the ill-
ness course over the past year, all participants will
complete the retrospective version of the LCM. Figure 3
shows a summary of measures of study 2.
Intervention
Investigational treatment will be STEPPS, as described
in the introduction, added to individual TAU (Treatment
As Usual) for BD. According to current guidelines for
treatment in BD [18] TAU consists of three necessary mod-
ules: pharmacotherapy, information and psycho-education,
and interventions to improve self-management.
Sample size
Inclusion of 64 patients for each group has a power of
80% and an alpha of 5% to detect an average difference
in Cohen’s d (0.50). Assuming a loss of 10% 140 patients
will be enrolled. Patients will participate in STEPPS
groups that are normally organized in the participating
centers, i.e., there are no groups exclusively set up for
this research population. The rationale is that in clinical
practice, patients with BD and comorbid borderline per-
sonality features will be treated in routinely organized
STEPPS groups, together with patients with a primary
diagnosis of BPD.
Statistical analyses
Differences in baseline data between the STEPPS condi-
tion and TAU condition are analyzed by t-test for con-
tinuous variables (demographic characteristics and
scores on the outcome variables). Differences in utilizing
mental healthcare between both groups will also be ana-
lysed by t-test. Categorical variables will be analyzed by
chi-square. Both groups will be compared to an average
number of symptomatic days/year, differentiated accord-
ing to severity (LCM).
Linear Mixed Model (LMM) under the missing at ran-
dom (MAR) will be used to analyze questionnaires data:
the severity of manic and depressive symptoms (IDS-SR &
YMRS), severity and course of borderline symptoms
(BPDC-47 & PAI-BOR), psychological and somatic dis-
tress (BSI total score) and quality of life (OQ-45 & WHO-
Qol Bref).
Ethical review and trial registration
This RCT has been reviewed and approved by the
ethics committee of the VU University Medical Center in
Amsterdam, The Netherlands (registration number: 2012/
470). It is registered in www.trialregister.nl (trial ID:
NTR4016).
Discussion
To our knowledge there is little known about the effect-
iveness of psychological treatment in patients with BD en
comorbid BPD. This will be the first randomized con-
trolled trial to test the efficacy of an integrated treatment
consisting of a cognitive behavioral skills training next to
TAU in this specific population. The relationship between
BD and BPD is still subject of controversy. In a review
Paris et al. [38] conclude that BPD and BD may co-occur,
but their relationship is not consistent or specific. More
knowledge about co-occurrence and comorbidity of these
disorders may have an important clinical relevance in
order to plan appropriate treatment [39]. It is expected
that a psychological treatment aimed at improving emo-
tion regulation will have a positive effect on symptoms of
personality disorder as well as BD, and will contribute to
an increased quality of life and less care consumption in
patients with complex emotional instability.
Life-Chart*
one year
before entry
(retrospective)
and during
entire study
(prospective)
-12 month 0 month 6 month 12 month 18 month
Baseline
(T0)
Post
(T1)
Follow-
up (T2)
Follow-
up (T3)
BSI* X X X X
IDS-SR* X X X X
YMRS* X X X X
BPDC-
47*
X X X X
OQ-45* X X X X
WHOQol
Bref*
X X X X
PAI-
BOR*
X X X X
PAM* X X X X
BPDSI*** X
Figure 3 measurements of study 2. Note: *self-rated **observer rated ***interview.
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